Clinical trials: Leucovorin
Biliary Tract Cancer
Liposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer
This is a prospective, single-arm, exploratory interventional study designed to evaluate the efficacy and safety of liposomal irinotecan (II) plus fluorouracil/leucovorin (5-FU/LV) and sintilimab with sequential stereotactic body…
- Trial name
- NCT07797816
- Testing
- Irinotecan Hydrochloride Liposome Injection (II), Fluorouracil, Leucovorin
- Where
- China
- Volunteers
- 31 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers.
- Conditions
- Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
- Trial name
- NCT06428409
- Testing
- Sacituzumab tirumotecan, Fluorouracil (5-FU), Leucovorin (LV) or levoleucovorin
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Recurrent Rectal Cancer
Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)
This is an open-label, single arm, phase 2 study. The study is to evaluate the activity of combination therapy of hypofractionated radiotherapy, Irinotecan Hydrochloride Liposome plus 5-FU and leucovorin (NALIRIF), Anti-PD1 and…
- Trial name
- NCT07183865
- Testing
- radiotherapy, Irinotecan Hydrochloride Liposome, 5-FU
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCC
Hepatocellular carcinoma patients are mostly diagnosed at locally advanced stage. Nowadays, hepatic artery interventional therapy and/or systemic therapy are the main treatments options for these patients.
- Trial name
- HAICPD1-HCC (NCT03869034)
- Testing
- HAIC+PD1, HAIC
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP
To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia (PCP) in AIDS patients TMTX is an experimental new drug…
- Trial name
- NCT00000998
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Participants
A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants
The aim of this study is to assess the effect of coadministration of multiple oral doses of BMS-986322 with rosuvastatin, metformin, and methotrexate in healthy participants.
- Trial name
- NCT05615012
- Testing
- BMS-986322, Rosuvastatin, Metformin
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Inoperable œsophageal Cancer
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
The main objective of the trial is to assess the feasibility and the safety of the addition of immunotherapy with PD-1 antibody nivolumab +/- CTLA-4 antibody ipilimumab to concomitant chemoradiation therapy (CRT) in inoperable…
- Trial name
- CRUCIAL (NCT03437200)
- Testing
- Nivolumab, Ipilimumab, Chemoradiation
- Where
- 7 sites in France, Spain
- Volunteers
- 8 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Colorectal Cancer
Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer
Neoadjuvant chemoradiotherapy (CRT) followed by total mesenteric excision (TME) and adjuvant chemotherapy was the standard of treatment for locally advanced rectal cancer (LARC) in the past two decades.
- Trial name
- OPTICAL-2 (NCT05571644)
- Testing
- mFOLFOXIRI + Cadonilimab, mFOLFOX6, mFOLFOXIRI
- Where
- China
- Volunteers
- 143 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Colorectal Cancer
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or…
- Conditions
- Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma
- Trial name
- NCT04553692
- Testing
- Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars)
- Where
- 58 sites in United States, Australia and 3 more
- Volunteers
- 272 people
- Sponsor
- IGM Biosciences, Inc.
Metastatic Pancreatic Cancer
Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma
Splenomegaly is common in advanced pancreatic ductal adenocarcinoma (PDAC). The spleen is an important source of immune suppressive cells and phagocytic cells and may mediate the accumulation of liposomal drugs and…
- Trial name
- SINAI (NCT05363007)
- Testing
- nanoliposomal irinotecan, spleen irradiation
- Where
- 2 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Colorectal Cancer
A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.
This open-label study will assess the efficacy and safety of Avastin (bevacizumab) plus Xeloda (capecitabine) in combination with standard technique radiotherapy of the pelvic region in the neo-adjuvant setting in patients with…
- Trial name
- NCT01227707
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda], Radiation therapy
- Where
- 9 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and fluorouracil alone in treating patients who…
- Conditions
- Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7
- Trial name
- NCT00096278
- Testing
- Bevacizumab, Fluorouracil, Leucovorin Calcium
- Where
- United States
- Volunteers
- 2,710 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
Hepatic artery infusion chemotherapy (HAIC) is effective and safe for hepatocellular carcinoma (HCC). Recombinant Human Type-5 Adenovirus (H101) is safe for HCC.
- Trial name
- NCT03780049
- Testing
- HAIC of FOLFOX, H101
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given…
- Trial name
- AndroMETa-CRC (NCT06820463)
- Testing
- Telisotuzumab Adizutecan, Fluorouracil, Oxaliplatin
- Where
- 82 sites in United States, Australia and 13 more
- Volunteers
- 390 people
- Sponsor
- AbbVie
Colorectal Cancer Metastatic, Colorectal Cancer Stage III
COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer
This is an early phase I, single-arm, open-label clinical study designed to evaluate the safety, tolerability, and feasibility of COLONYVAQ-CRC, a physics-aware, quantum-classical AI-guided personalized neoantigen peptide…
- Conditions
- Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV
- Trial name
- COLONYVAQ™-CRC (NCT07328087)
- Testing
- Experimental: COLONYVAQ-CRC + mFOLFOX6 or CAPOX + Nivolumab
- Where
- Greece
- Volunteers
- 12 people
- Sponsor
- Biogenea Pharmaceuticals Ltd.
Peritoneal Mesothelioma, Gestational Trophoblastic Tumor
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, most rare cancers have been excluded from this progress due to the lack of clinical trials involving these diseases.
- Conditions
- Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- IMMUNORARE5 (NCT06790706)
- Testing
- DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4
- Where
- 15 sites in France
- Volunteers
- 27 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Adenocarcinoma, Mucinous Adenocarcinoma
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
Hypothesis: Patients with metastatic colorectal cancer with DNA mismatch repair-proficient (pMMR) function / microsatellite-stable (MSS) phenotype harbor a non-immunogenic disease that can be transformed into an immunogenic…
- Conditions
- Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma
- Trial name
- METIMMOX-2 (NCT05504252)
- Testing
- Nivolumab, Oxaliplatin
- Where
- 3 sites in Norway
- Volunteers
- 80 people
- Sponsor
- University Hospital, Akershus
Solid Tumors
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could increase its therapeutic potential.
- Trial name
- NCT00044785
- Testing
- triacetyluridine, fluorouracil, leucovorin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wellstat Therapeutics
Pancreatic Cancer Non-resectable, Chemotherapy Effect
Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer
In patients diagnosed with locally advanced pancreatic cancer (LAPC)/borderline resectable pancreatic cancer (BRPC) and planned chemotherapy using FOLFIRINOX, high intensity focused ultrasound (HIFU)/FOLFIRINOX combined treatment…
- Conditions
- Pancreatic Cancer Non-resectable, Chemotherapy Effect, Ultrasound Therapy
- Trial name
- NCT05262452
- Testing
- ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system, FOLFIRINOX regimen
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Locally Advanced Pancreatic Adenocarcinoma
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
The aim of this study is to demonstrate the efficacy of intensified and sequential chemotherapy (Gabrinox) comprising Gembrax regimen (Gemcitabine-Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) in…
- Trial name
- GABRINOX-ART (NCT04570943)
- Testing
- Gabrinox, MRI-GUIDED STEREOTACTIC RADIOTHERAPY
- Where
- 9 sites in France
- Volunteers
- 103 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.